|
Device-oriented composite endpoint*
|
18 (12.0)
|
5 (6.6)
|
13 (17.6)
|
–11.0 (–21.3 to –0.7)
|
0.038
|
|
Patient-oriented composite endpoint¶
|
32 (21.3)
|
14 (18.4)
|
18 (24.3)
|
–5.9 (–1.9 to 0.07)
|
0.378
|
|
Death
|
4 (2.7)
|
3 (3.9)
|
1 (1.4)
|
2.6 (–2.5 to 7.7)
|
0.324
|
|
Cardiac death
|
2 (1.3)
|
1 (1.3)
|
1 (1.4)
|
0.1 (–3.7 to 3.6)
|
0.985
|
|
Myocardial infarction
|
6 (4.0)
|
4 (5.3)
|
2 (2.7)
|
2.6 (–3.7 to 8.8)
|
0.424
|
|
Related with device thrombosis
|
3 (2.0)
|
2 (2.6)
|
1 (1.4)
|
1.3 (–3.2 to 5.7)
|
0.576
|
|
Spontaneous
|
3 (2.0)
|
2 (2.6)
|
1 (1.4)
|
1.3 (–3.2 to 5.7)
|
0.576
|
|
Definite/probable device thrombosis
|
3 (2.0)
|
2 (2.6)
|
1 (1.4)
|
1.2 (–3.2 to 5.7)
|
1.000
|
|
Re-percutaneous cardiac intervention
|
17 (11.3)
|
9 (11.8)
|
17 (23.0)‡
|
–11.2 (–23.2 to 0.9)
|
0.072
|
|
Target lesion revascularisation
|
16 (10.7)
|
4 (5.3)
|
12 (16.2)
|
–10.9 (–20.7 to –1.2)
|
0.030
|
|
Ischaemia driven
|
16 (10.7)
|
4 (5.3)
|
12 (16.2)
|
–10.9 (–20.7 to –1.2)
|
0.030
|
|
Target vessel revascularisation
|
21 (14.0)
|
6 (7.9)
|
15 (20.3)
|
–12.4 (–23.4 to –1.4)
|
0.029
|
|
Non-target vessel revascularisation
|
6 (4.0)
|
3 (3.9)
|
3 (4.1)
|
–0.2 (–6.4 to 6.2)
|
0.973
|
|
Any bleeding§
|
10 (6.7)
|
7 (9.5)
|
3 (4.1)
|
–5.5 (–13.5 to 2.5)
|
0.176
|
|
Values are n (%). *Device-oriented composite endpoint is defined as the composite of cardiac death, target vessel myocardial infarction, and target lesion revascularisation. ¶Patient-oriented composite endpoint is defined as the composite of all-cause death, any myocardial infarction, and any revascularisation. ‡One patient had a non-target vessel and target lesion revascularisation. §Any bleeding was defined as BARC 1 to 5. 95% CI: 95% confidence interval; BARC: Bleeding Academic Research Consortium definition; MgBRS: magnesium-based bioresorbable scaffold; SES: sirolimus-eluting stent
|
